Our initial research and development efforts have focused on drug candidates targeting selectins, which are adhesion molecules that are principally involved in the inflammatory component and progression of a wide range of conditions. Our expertise in glycobiology has enabled us to advance several highly-potent selectin antagonists into late-stage clinical development for the treatment of individuals with sickle cell disease and acute myeloid leukemia. In addition, we are developing several other glycomimetic drug candidates that may address unmet medical needs in a variety of solid tumor and fibrotic diseases.
